Enrollment Completed – Ongoing Studies

Sponsor: AbbVie  Protocol: M13-594

Title: A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection

 

Sponsor: AbbVie  Protocol: M14-172

Title: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotypes 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

 

Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-380-1961

Title: A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) from Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women

 

Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-380-1490

Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

 

Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-380-1489

                                    Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

 

Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-380-1878

Title: A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

 

Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-380-1844

Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed

 

Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-292-1825

                                    Title: A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis

 

Sponsor: Janssen   Protocol: TMC114FD2HTX3001

Title: A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination coadministered with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects.

 

Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-311-1717

                                    Title: A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC

 

Sponsor: ViiV Healthcare   Protocol: GSK201636

                                    Title: A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed

 

Sponsor: Bristol-Myers Squibb   Protocol: AI438-047

Title: A Multi-Arm Phase 3 Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced (HTE) Human Immunodeficiency Virus-1 (HIV-1) Infected Subjects Infected with Multi-drug Resistant (MDR) HIV-1

 

Sponsor: Janssen   Protocol: TMC114IFD3013

                                    Title: A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects.

 

Sponsor: Gilead Sciences, Inc.   Protocol: GS-US-366-1160

Title: A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects.

 

Sponsor: Gilead Science, Inc.   Protocol: GS-US-366-1216

                                    Title: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine /Tenofovir Disoproxil Fumarate (FTC/RPV/TDF).

 

Sponsor: Merck   Protocol: MK1439-018

                                    Title: A Phase 3 Multicenter, Double-blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100mg Once Daily Versus Darunavir 800mg Once Daily plus Ritonavir 100mg Once Daly, Each in Combination with Truvada or Epzicom/Kivexa, in Treatment-Naïve HIV-1 Infected Subjects.

 

Sponsor: ViiV Healthcare   Protocol: GSK200056

Title: A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral regimen of GSKI 126 plus Abacavir/Lamivudine in HIV-1 infected, Antiretroviral Therapy-Naïve Adult Subjects. 

 

Gilead Sciences - 0114 Study

 

 

 

 
 
 

Fort Pierce FL HIV & AIDs Treatment

Fort Pierce FL Hepatitis C Treatment, General ID & Clinical Trials

Call us at: (772) 595-9830
 
356 Midway Rd,
Fort Pierce, FL 34982